Eptifibatide

CAS : 188627-80-7

Ref. 3D-EPT-3786-PI

Informations sur le produit

• Nom: Eptifibatide
• Synonymes: [3-carbamoyl-11-{4-[(diaminomethylidene)amino]butyl}-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid, [(1S,4R,12S,18S,21S)-12-(4-carbamimidamidobutyl)-4-carbamoyl-21-(1H-indol-3-ylmethyl)-2,10,13,16,19,22-hexaoxo-6,7-dithia-3,11,14,17,20,26-hexaazabicyclo[21.2.1]hexacos-18-yl]acetic acid, Map-Lys-Gly-Asp-Trp-Pro-Cys-Nh2, Integrelin, N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid, Eptifibatide Acetate
• CAS: 188627-80-7

Description

Eptifibatide is a drug that is used in the treatment of congestive heart failure, acute coronary syndrome and peripheral artery disease. It is a glycoprotein IIb/IIIa inhibitor that binds to integrin receptors on platelets and prevents them from binding to fibrinogen. This prevents blood clotting and reduces the risk of stroke or heart attack. Eptifibatide has been shown to be effective for the treatment of bowel disease, infectious diseases, and experimental models of myocardial infarcts. The drug has significant cytotoxicity, which may be due to its ability to inhibit cell proliferation by blocking protein synthesis at the ribosome level.
Eptifibatide has been shown to have a disulfide bond between two cysteine residues located in its amino-terminal region. This bond stabilizes the molecule in solution and ensures that it remains active until it reaches its target site.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 831.98 g/mol
• Formule: C₃₅H₄₉N₁₁O₉S₂
• Degré de pureté: Min. 95%